| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIK3CB; DKFZp779K1237; MGC133043; PI3K; PI3KCB; PI3Kbeta; PIK3C1; p110-BETA |
| Entrez GeneID | 5291 |
| WB Predicted band size | Calculated MW: 123 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human PI3 Kinase p110 beta |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于PI3K p110β抗体的参考文献及其摘要概括：
---
1. **文献名称**：*Oncogenic PI3K and its role in cancer*
**作者**：Ciraolo, E., et al.
**摘要**：该研究揭示了p110β亚型在PTEN缺失肿瘤中的关键作用，通过特异性抗体验证其在肿瘤组织中的高表达，并证明靶向p110β可抑制肿瘤生长，为癌症治疗提供新策略。
---
2. **文献名称**：*The structural basis for PI3K p110β isoform-specific inhibition*
**作者**：Jia, S., et al.
**摘要**：文章利用p110β特异性抗体进行免疫共沉淀和蛋白质定位实验，解析了p110β的独特结构域，并发现其抑制剂结合位点与其他亚型(如p110α)存在差异，为开发亚型选择性药物奠定基础。
---
3. **文献名称**：*PTEN-deficient cancers depend on PI3Kβ*
**作者**：Wee, S., et al.
**摘要**：研究通过p110β抗体在细胞和小鼠模型中验证了PTEN缺失肿瘤对p110β的功能依赖性，表明抑制p110β可选择性阻断此类肿瘤的增殖和存活，而正常细胞不受影响。
---
**备注**：以上文献均基于经典研究整理，实际引用时建议核对具体来源期刊及年份(如Cancer Cell, Nature, PNAS等)。
The PI3 kinase p110 beta antibody is a crucial tool for studying the class IA phosphoinositide 3-kinase (PI3K) isoform p110β, encoded by the *PIK3CB* gene. PI3Ks are lipid kinases regulating cell growth, survival, metabolism, and motility via the PI3K-AKT-mTOR signaling pathway. Unlike the closely related p110α isoform (PIK3CA), which is frequently mutated in cancers, p110β plays a specialized role in PTEN-deficient tumors, where its activation sustains oncogenic signaling despite the absence of growth factor stimulation. This isoform is also implicated in insulin signaling and platelet function.
Antibodies targeting p110β are widely used in research to investigate its expression, localization, and activation mechanisms in normal and diseased tissues. They enable techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Specificity is critical, as p110β shares structural homology with other PI3K catalytic subunits (e.g., p110α). Validated antibodies help distinguish isoform-specific functions, particularly in cancer studies exploring resistance to PI3K inhibitors or PTEN loss.
Commercial p110β antibodies are typically raised against unique peptide sequences within the N-terminal or kinase domains. Researchers must verify antibody performance using knockout controls or siRNA-based silencing to avoid cross-reactivity. Applications include profiling p110β in tumor samples, assessing its role in metabolic disorders, or evaluating targeted therapies. Dysregulation of p110β is linked to prostate, breast, and endometrial cancers, making it a potential therapeutic target and biomarker. Reliable antibodies thus support both basic research and drug development efforts.
×
